Samsung Biologics Clears the Tender Threshold: What PolyPeptide's Imminent Delisting Means for Peptide API Supply

Key takeaways

• The additional acceptance period for Samsung Biologics' all-cash tender for PolyPeptide Group AG closed on 30 October 2026; the main period had already returned an 87.59–87.92% tender rate, well above the 66.7% minimum condition.
• Settlement is expected within ten trading days of multi-jurisdiction regulatory clearance from authorities in Europe, India, Australia, and Brazil, with a target completion date of end-November 2026.
• Samsung Biologics has announced a KRW 3 trillion rights offering to fund the acquisition and future capacity investment, signalling intent to expand rather than merely absorb PolyPeptide's existing footprint.
• PolyPeptide will be delisted from the SIX Swiss Exchange and operated as a wholly owned subsidiary; a squeeze-out of remaining minority shareholders is planned if Samsung's stake exceeds 90%.
• For research procurement teams, the immediate practical question is continuity: PolyPeptide currently supplies peptide APIs — including GLP-1-related compounds — to clients across the US, Europe, and India, and a change of beneficial ownership at this scale historically prompts contract review cycles.

Where the deal stands as of 31 October

Samsung Biologics signed its transaction agreement with PolyPeptide Group on 17 July 2026, and launched the formal all-cash tender at CHF 44.31 per share through its Swiss special-purpose vehicle, Samsung Peptide AG, on 31 August 2026. The main acceptance period ran from 15 September to 12 October.

Provisional interim results published on 13 October showed Samsung Peptide holding 87.92% of PolyPeptide's issued share capital, with 87.59% validly tendered during the offer period itself. The definitive interim result, confirmed on 16 October, declared the minimum acceptance condition satisfied.

An additional acceptance window then ran from 19 to 30 October 2026, closing yesterday. According to Samsung Biologics and PolyPeptide's public disclosures, the company intends to pay for tendered shares and close the transaction within ten trading days of receiving the outstanding regulatory approvals from European, Indian, Australian, and Brazilian authorities. The target remains end-November 2026, though one filing notes the possibility of completion extending into Q1 2027 should any regulatory clearance be delayed.

An extraordinary general meeting of PolyPeptide shareholders, held on 26 October, addressed the corporate governance conditions required under Swiss takeover law, including board composition changes. Samsung Peptide has also announced plans for a squeeze-out of any remaining minority holders and a delisting from the SIX Swiss Exchange, at which point PolyPeptide will become a wholly owned subsidiary.

What PolyPeptide brings to Samsung

PolyPeptide Group is one of the largest specialist peptide CDMOs in the world, with manufacturing sites across Switzerland, France, Sweden, the United States, and India. According to BioProcess International, the transaction enables Samsung Biologics to expand its capabilities beyond antibodies, messenger RNA, and antibody-drug conjugates to include peptide therapeutics — "one of the fastest-growing segments of the biopharmaceutical industry."

Industry commentary, including analysis tracked by Biobucks, has characterised the acquisition as Korea's largest-ever biopharma transaction and a direct bet on GLP-1 peptide API capacity, which cannot be built greenfield on a short timeline. PolyPeptide reported H1 2026 revenue of approximately USD 271 million, up 41.6% year on year, reflecting sustained demand pressure from the obesity drug pipeline.

Samsung Biologics' Q3 2026 results showed quarterly revenue of KRW 1.49 trillion, with the company raising its full-year 2026 revenue growth guidance to 20%. Plants 1 through 4 operated at full capacity during the quarter, with Plant 5 contributing increasingly as production ramped. Separately, Samsung has announced a KRW 3 trillion rights offering to support the PolyPeptide purchase and future capital expenditure.

The broader CDMO consolidation picture

The Samsung/PolyPeptide deal is the headline transaction in a broader wave of peptide manufacturing consolidation that has accelerated throughout 2026. CordenPharma's acquisition of AmbioPharm, adding US purification and lyophilisation capacity in South Carolina, and Siegfried's purchase of three US and Australian drug-substance sites from SK Capital are among the complementary moves that have re-drawn the CDMO landscape this year.

Industry trackers estimate that announced peptide CDMO investments crossed USD 2.4 billion year-to-date in 2026, with the primary driver being GLP-1 drug demand. Yet lead times for large-scale solid-phase peptide synthesis capacity additions remain 18–36 months, meaning the capital now being committed will not translate into deliverable capacity before late 2028 at the earliest. In the near term, ownership changes at major CDMOs consolidate negotiating leverage rather than expand output.

Procurement implications for UK research laboratories

Several operational considerations follow directly from PolyPeptide's imminent change of beneficial ownership.

Contract continuity. Standard terms in peptide API supply agreements typically contain change-of-control notification clauses. Laboratories holding active supply arrangements with PolyPeptide — or with contract research organisations that source from it — should verify whether any such clause has been triggered and confirm that lead times, minimum order quantities, and quality agreements remain in force under the new ownership structure.

Quality system transition. An acquisition of this scale normally initiates an internal quality management system harmonisation between acquirer and target. During that period, Certificate of Analysis (CoA) issuing entities, lot numbering conventions, and audit contact points may change. Procurement officers should request written confirmation from PolyPeptide's existing account managers of any changes to CoA issuance or batch release procedures as the transaction closes.

Supply allocation risk. Samsung Biologics has stated its intent to combine PolyPeptide's specialised expertise with its own large-scale manufacturing experience and to consider expanding capacity as demand grows. In the near term, however, the priority allocation of newly integrated capacity is likely to follow strategic priorities set by Samsung's large biopharma clients rather than smaller research-volume customers. Laboratories that currently rely on PolyPeptide for research-grade GLP-1 or other therapeutic peptide APIs should identify at least one qualified alternative supplier as a contingency.

Pricing. The rights offering and leverage used to fund the CHF 1.46 billion acquisition carry a financing cost that Samsung will need to absorb across PolyPeptide's revenue base. Historical patterns in CDMO consolidation suggest that pricing pressure flows most immediately to lower-volume or spot-purchase customers. Annual pricing reviews in 2027 may reflect this dynamic.

Next milestones to watch

The definitive final result — covering both the main and additional acceptance periods — is expected to be published shortly, and will confirm the precise stake Samsung holds ahead of any squeeze-out procedure. BSR Intelligence will update procurement readers when that announcement is made.

Research procurement teams with active PolyPeptide supply relationships are advised to contact their account managers directly to confirm contract continuity terms prior to transaction close.